莱美药业：关于控股子公司获得药物临床试验批准通知书的公告

Core Viewpoint - Recently, Chongqing Laimei Pharmaceutical Co., Ltd. announced that its subsidiary Sichuan Yingrui Pharmaceutical Technology Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of its innovative anti-cancer drug "Nano Carbon Iron Suspension Injection" in combination with standard radiotherapy for solid tumor patients [2] Company Summary - Laimei Pharmaceutical's subsidiary, Sichuan Yingrui, has developed an innovative anti-cancer drug [2] - The drug has received a clinical trial approval notification from the National Medical Products Administration [2] - The clinical trials will focus on the use of the drug in conjunction with standard radiotherapy for patients with solid tumors [2]